Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2000-12-08
2004-08-24
Rao, Manjunath (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S004000, C435S006120, C435S183000, C435S195000, C426S002000, C426S056000, C426S531000
Reexamination Certificate
active
06780628
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a composition comprising and methodology for using enzymes, as anti-infection agents, in the context of treating or lowering the risk of digestive tract infections.
BACKGROUND OF THE INVENTION
In its 1998 Revision of the World Population Estimates and Projections, the United Nations Department of Economic and Social Affairs Population Division projected that the world population would reach 6 billion in 1999. The report also stated that it took only 12 years for the population to increase from 5 to 6 billion compared to 123 years to go from one to two billion. By the mid 21st century the projected population is between 7.3 and 10.7 billion. The remarkable population growth in the last decade is due partly to the efficient gains in food production resulting from the application of technology and intensive food production practices. For future growth, more efficiency gains in food production will be needed to keep pace.
One approach, which has made animal meat production more efficient, involves the widespread use of anti-microbial chemicals and antibiotics in animal feed. In large-scale farms, the spread of infection is very fast under the crowded production conditions. Widespread disease therefore is controlled by prophylactic and therapeutic uses of these substances. For example, it is common practice to incorporate chemicals in animal feeds to control coccidia infections (e.g., salinomycin, monensin, roxarsone (3-nitro), halquinol, carbadox and olaquindox) as well as anti-microbial antibiotics (e.g., bacitracin, virginiamycin, tylosin, tetracycline, chlortetracycline, penicillin, oleandomycin, novobiocin, lincomycin, bambermycins, apramycin, spiramycin, erythromycin, neomycin and others). This practice is well known to promote growth and improve feed conversion.
The rise in multiple antibiotic resistance among human pathogens, such as
Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Neisseria gonorrhoeae
, and
Mycobacterium tuberculosis
, has created fear that antibiotic resistance developed in microbes associated with farm animals could be migrating to human pathogens through transferable drug resistance factors. There is evidence that animals fed with antibiotics are a source of bacteria with transferable resistance factors. See Hooge,
Feedstuffs
71(20):59, 1999. Although the antibiotics used in animals and in humans are generally different, there are similarities in mechanisms that could result in cross-resistance. In one case, fluroquinolones are approved for control of
E. coli
infections (colibacillosis) in some animals and also are used in human medicine. Hooge, supra. Recently the FDA/CVM has proposed to withdraw the approval to use the fluroquinolone enrofloxacin in poultry due to the development of fluoroquinolone-resistant campylobacter and transfer to humans. See Murhead, S.
Feedstuffs
72(45):1-4, 2000.
There also is a concern among meat-producing industries that yield loss and possible resurgence of animal disease could occur if there is a ban on use of antibiotics and antimicrobials in feed. In 1986, for example, Sweden banned the use of feed antibiotics and animal disease increased. This was accompanied by an increased use of therapeutic antibiotics that resulted in an overall increase in the use of antibiotics as well as increased meat animal production costs. See Smith,
Feedstuffs
71(13):1, 1999. In December 1998, the EU Council of Ministers decided to suspend the use of six antimicrobials that were formally approved as prescription-free in feed growth promoters (
Official Journal of the European Communities
29.12.98, Council Regulation No. 2821/98 concerning Directive 70/524). Two quinoxaline-based additives were also banned in August 1999 due to concern about residues in the meat. The result of these actions is an increased prevalence of conditions formally suppressed including: necrotic enteritis in broilers; enteritis due to
Clostridium perfringens
in weaned pigs; swine dysentery and spirochaetal diarrhoea; and
E. coli
-associated diarrhoea. See Miller,
United States Animal Health Association
, 1999 Proceedings “Antibiotic Usages in Food Animal Production and Resistance-European Perspective.”
There are 30,000 human deaths per year caused by nosocomial infections with resistant pathogens, but many fewer deaths from food borne pathogens. None of the deaths from food-borne pathogens have been linked to antibiotic resistance (see Smith, supra). Thus, it is not clear whether the use of antibiotics by the meat producing industries has contributed to the drug-resistant pathogen problem of the nosocomial infections in humans. Another concern is the lack of new antibiotics to treat infections with resistant pathogens. See Henry, C. M.,
Chemical and Engineering News
, Mar. 6, 2000, pp 41-58. This could mean that when significant antibiotic resistant pathogens develop, there may be no new antibiotics available to treat the infections. The difficulty of developing antibiotics, market size, and regulatory issues seem to have caused the major pharmaceutical companies to move their R&D focus away from antibiotics development, especially for use in animals. New proposed regulations for registering a drug for animal use are so difficult that development is being stopped. See Smith, supra. There are, however, several small companies involved in the development of new antibiotics (Henry, supra).
In certain animal populations, infection is already pandemic. For example, avian coccidiosis is a disease that is only managed, but not really under control. Virtually all flocks are infected and anti-coccidiosis chemicals are commonly rotated in the feed to control damage and limit the development of resistant strains. Coccidiosis costs poultry producers $350 million annually in losses and medication expenses for antibiotic drugs such as salinomycin. See Suszkiw,
USDA Agricultural Research Service News
, Oct. 28, 1997. By 1999, it has been estimated that about $114 million would be spent annually on coccidiostats in the United States. See Frost & Sullivan,
U.S. Pharmaceutical Products for Food Animals
, Report 5245-54, 1995.
There is a clear need to find new and more effective methods to control infections in the digestive tract of animals that are grown using intensive farming practices. This need is based on a requirement to obtain better production efficiency in order to keep up with the rapidly expanding world population. Improved control of intestinal infection guarantees faster growth rate and improved feed efficiency. There is also a need for alternatives to antibiotic use in animal production to address the concern for possible antibiotic resistance development in human pathogens.
There is no risk of stimulating the evolution of resistant pathogenic microorganisms that present a problem for human health when using an enzyme-based treatment that operates in a manner different from all antibiotics. Since enzymes are proteins, there is no possibility that dangerous chemical residue will be incorporated in the meat products, as happens with some antibiotics and anti-coccidiosis chemicals. See American Feed Control Officials Inc.,
Official Publication
, 1999, “Drugs and Feed Additives, Section 30.0 Enzymes,” pp. 206-217, ISBN 1-878341-10-3.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to provide an enzymatic treatment to reduce the impact of digestive tract infections.
It is another object of the present invention to provide a mechanism to reduce the impact of digestive tract infections by interfering with the binding of pathogens to the cells of the digestive tract.
It is yet another object of the invention to provide an approach for increasing weight gain and feed conversion with respect to animals that are infected with pathogens which cause infections or necrotic enteritis.
It is a further object of the present invention to provide a dosage form, suitable for oral administration that is effective in improving the condition of a subject infected by
Anderson David M.
Fodge Douglas W.
Hsiao Humg-Yu
Liu Lin
Chemgen Corporation
Foley & Lardner LLP
Rao Manjunath
LandOfFree
Enzyme treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzyme treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3333946